JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety
of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed
previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the
secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w,
lenvatinib 8mg po. Qd.